PW Medtech subsidiary, Sichuan Ruijian, reports strong Q1 growth

PW Medtech Group Limited announced the unaudited first-quarter results for its subsidiary, Sichuan Ruijian Medical Technology Co. Ltd. Revenue reached RMB145,036,095.85, a 43.89% increase compared to the same period in 2024, driven by expansion in domestic and overseas markets. Profit before tax rose by 16.96% to RMB42,782,684.84, while net profit attributable to shareholders of Sichuan Ruijian Medical reached RMB36,171,069.91, a 15.68% increase. The company also disclosed that Sichuan Ruijian Medical received a review inquiry letter from the Beijing Stock Exchange regarding its application for public stock issuance and listing. PW Medtech stated it is working to address the inquiry.